A systematic approach toward building activity against methicillin-resistant staphfocused on finding the optimal linkage between the cephem nucleus and a biphenyl pharmacophore, which established that a thio linkage afforded potent activity in vitro. Efforts to optimize this activity by altering substitution on the pharmacophore afforded iodophenylthio analog MC-02,002, which although highly potent against MRSA, was also highly bound to serum proteins. Further work to decrease serum protein binding showed that replacement of the iodo substituent by the positively-charged isothiouronium group afforded potent activity and reduced serum binding, but insufficient aqueous solubility. Solubility was enhanced by incorporation of a second positively-charged group into the 7-acyl substituent. Such derivatives (MC-02,171 and MC-02,306) lacked sufficient stability
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The emergence of staphylococci resistant to all curAt the time we initiated this approach, we were aware of three other ongoing programs in this area ( Fig. 1) , at Merck2) (2-biaryl carbapenems, 1), Eli Lilly3) (3-thiazolylthiocarbacephems, 2) and Meiji Seika4) (3-benzothiazolylthiocephems, 3) . Among the various an appropriate (oximino) acetyl 7-substituent, as is found in many extended-spectrum cephalosporins. Our initial work began with attachment of a biphenyl pharmacophore to a cephem nucleus, since earlier work by the Table 2 ; the general method by which these compounds were prepared is shown in Scheme 2. Two key results were identified: i) that the distal phenyl group could be replaced with another lipophilic substituent, such as halogen, but polar functionalities reduced activity, and ii) that the optimal point of substitution of the lipophilic group was the 2-position of the phenylthio moiety. The most potent compound of this series was the 2-iodophenylthio analog 21 (MC-02,002), which displayed excellent potency against both MRSA and enterococci.
Further Profiling of Early Lead MC-02,002
The compelling in vitro activity in the primary microbiological panel prompted extensive evaluation of MC-02,002, which included determinations of MIC90 values, affinity for PBP2a, solubility, efficacy in a mouse septicemia model, and binding to human serum proteins. Notably, the in vitro potency against both MRSA and MRCNS is impressive (Table 3) , and in fact is in line THE JOURNAL OF ANTIBIOTICS 725 To reduce the serum binding of MC-02,002, the effects of various substituents on both serum binding and antibacterial activity were studied. While we did not set a particular target for an appropriate serum binding level, we were cognizant that the term MIC/fu (fu is the fraction unbound) is an important determinant of efficacy against an infection, since this corresponds to the theoretical total drug concentration required to inhibit bacterial growth in vivo. Based on typical pharmacokinetic profiles of cephalosporins, and the knowledge that cephalosporin efficacy is generally associated with maintenance of unbound serum drug concentrations above the MIC for >50% of the dosing interval,7) we estimated that we would need to keep the MIC90/fu ratio at about 10 or less. For a compound having the potency of MC-02,002 target of 80% (unbound fraction=0.2).
The effects of various structural changes on both activity and human serum binding are shown in Table  4 The insolubility of compound 32 can be attributed to the fact that it exists as a zwitterion at neutral pH. In order to improve its solubility, we sought to introduce a third charged functional group at the 7-position ( The results of evaluation of this series of analogs in which the 7-substituent is varied are shown in Table  6 of dimethyl 4-(N, N-dimethylcarbamoylthio) isophthalate was stirred at reflux for 4 hours and the mixture was concentrated. The residue was dissolved in 500ml of
The aqueous layer was adjusted to pH 3 with concentrated hydrochloric acid, and was extracted with ethyl phenylthio]-3-cephem-4-carboxylate, 4-methoxybenzyl ester, (bis) hydrochloride salt (4.40g, 3.70mmol) was taken up in 5% anisole/dichloroacetic acid (45ml). After 6 hours, the reaction was diluted with ether (450ml) and was stirred overnight. The mixture was filtered, the tan solid was washed with ether and dried, and was suspended in 0.1M ammonium acetate buffer (pH 6.0). A small amount of insoluble material was removed by filtration, and the resulting THE JOURNAL OF ANTIBIOTICS AUG. 1998 solution was subjected to medium-pressure chromatography on a 50ml Amberchrome column, eluting with 6.0). The fractions containing the desired product were concentrated on a rotary evaporator (to remove acetonitrile), and were lyophilized to afford 1.51g (60%)
